Buy CBD Pills 25mg

Product Overview

CBD Pills 25mg CAS 13956-29-1 constitutes a brandless, high-purity (≥98%) research chemical supplied exclusively for laboratory and analytical research. This encapsulated powder format delivers precise 25mg aliquots suitable for quantitative analytical workflows in professional research environments. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Researchers employ these standardized units for reproducible method development across HPLC, GC-MS, and NMR characterization platforms.

The pill configuration minimizes cross-contamination during multi-sample preparations while facilitating automated dissolution into mobile phases. Qualified investigators procure through compliant eCommerce channels to support systematic cannabinoid analog profiling and reference standard validations. Uniform capsule fill weights ensure gravimetric consistency essential for constructing calibration curves spanning five orders of magnitude.

Institutional analytical laboratories integrate CBD Pills 25mg into validated SOPs requiring characterized cannabinoids for QC matrices and inter-laboratory proficiency testing. Comprehensive batch certification streamlines LIMS incorporation while satisfying ISO 17025 accreditation criteria. Reliable supply chains prevent disruptions to longitudinal stability investigations and forced degradation studies.

This research chemical advances neutral structural analyses of phytocannabinoid isomers, providing objective physicochemical parameters for comparative chromatographic method optimization conducted exclusively under controlled laboratory conditions.

Chemical Identity & Classification

CBD Pills 25mg CAS 13956-29-1 contains CAS number 13956-29-1, molecular formula C21H30O2, and molecular weight 314.46 g/mol. Synonyms include Cannabidiol, (-)-trans-Cannabidiol, and 2-[(1R,6R)-3-methyl-6-prop-1-enylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol, classifying it as a phytocannabinoid reference standard for analytical chemistry applications. Formal designation restricts usage to laboratory reagent contexts.

IUPAC nomenclature (6aR,10aR)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol defines absolute stereochemistry critical for chiral separations. This precise identification enables discrimination from Δ8-THC and synthetic cannabinoid isomers during LC-HRMS workflows. Classification aligns with terpenophenolic reference materials employed in forensic toxicology and natural products research.

Calculated descriptors include cLogP 6.3, TPSA 40.5 Ų, three H-bond donors, supporting reversed-phase retention modeling across C18 and HILIC stationary phases. Synonym standardization facilitates PubChem/SciFinder retrieval while maintaining research-only boundaries.

Chemical & Physical Characteristics

CBD Pills 25mg delivers colorless to pale yellow crystalline powder encapsulated in vegetarian cellulose shells. Solubility profiles confirm ethanol (50 mg/mL), DMSO (100 mg/mL), DMF (75 mg/mL), and hexane (10 mg/mL) compatibility, enabling diverse extraction protocols. Thermal analysis registers melting point 66-67°C suitable for chiral HPLC method development.

Encapsulation ensures protection from aerial oxidation during ambient storage. UV absorbance maxima at 225, 276 nm optimize photodiode array detection sensitivity. pKa values (7.0 carboxylic, 9.5 phenolic) facilitate speciation studies across physiological pH gradients. Capsule disintegration follows USP <711> specifications (<15 min in 0.1N HCl).

Particle size distribution post-dissolution maintains D90 <50 μm, controlling chromatographic peak asymmetry. Low moisture content (<1.0% KF) preserves oxidative stability under standard laboratory conditions.

Purity & Analytical Verification

Purity exceeds 98%, validated via orthogonal techniques: RP-HPLC (>99.0% principal peak area), GC-FID, quantitative 1H-NMR, and APCI-LC-MS. Certificates of Analysis specify Δ9-THC <0.05%, CBN <0.1%, individual unknowns <0.10%, total impurities <1.0%. Residual solvents comply with ICH Q3C (ethanol <5000 ppm).

HPLC employs Waters BEH C18 (100×2.1 mm, 1.7 μm) with 0.1% formic acid/methanol gradient, resolving CBD from CBG/CBN (Rs >3.0). 500 MHz 1H-NMR (CDCl3) confirms diagnostic vinyl signals (5.4 ppm, dd, J=2.0,1.5 Hz), benzylic methyl singlets (1.4 ppm, 0.9 ppm), and pentyl chain triplets. HRMS validates [M+H]+ m/z 315.2319 (calc. 315.2319, Δ<1 ppm).

COAs append raw chromatograms overlaid with USP reference spectra. Method validation per ICH Q2 demonstrates linearity r²=0.9999 (5-500 μg/mL), accuracy 99.2-100.8% recovery, intermediate precision RSD <0.8%.

Quality Control & Batch Integrity

Batch synthesis utilizes carrier solvent-free supercritical CO2 extraction followed by winterization and flash chromatography. Lot traceability integrates from hemp biomass intake through final encapsulation via serialized blockchain logging. In-process Raman spectroscopy monitors polymorph conversion (Form I confirmed).

Release criteria encompass chiral purity (>99% single enantiomer), microbial enumeration (TAMC <100 CFU/g), and endotoxin (LAL <0.25 EU/mg). Third-party DEA-exempt laboratories execute duplicate blind analyses against NIST SRM 1572a. SPC maintains Cpk >1.67 across critical attributes.

Electronic batch records retain 10-year audit trails per 21 CFR 211.188. Accelerated stability (40°C/75%RH) confirms 36-month predictions.

Safety, Handling & Laboratory Precautions

Process exclusively under Type A/B3 ducted fume hoods (>100 fpm) wearing nitrile gloves (8 mil), chemical goggles, polyester lab coats, and P95 respirators. Conduct weighings within containment isolators (<1 μg/m³). SDS classifies Eye Irrit. 2A H319, STOT SE 3 H336.

HEPA-filtered glovebags contain fugitive powder during capsule opening. Spill protocol activates vermiculite absorption, 10% NaHCO3 neutralization, and sticky-mat decon. Segregate as non-hazardous waste per institutional EHS protocols.

Safety showers locate within 10-second access; annual competency training validates proficiency.

Packaging, Labeling & Storage

Encapsulated powder packages in 30-120 count HDPE bottles with child-resistant, desiccant-lined induction seals. GHS labels specify CAS, Lot, Purity, and NFPA 704 (H1,F1,R0). Primary containers employ USP <671> Type III packaging.

Storage mandates 15-25°C excursions permitted, light-protected from peroxides/nitrosamines. Photostability ICH Q1B confirms <0.5% degradation (1.2E6 lux-hours). UN3373 Biological Substances exempt air shipping.

Intended Research Use & Market Positioning

CBD Pills 25mg CAS 13956-29-1 supports forensic cannabinoid screening, Phase I metabolism mapping (CYP2C9/3A4/2C19), and receptor binding assays (CB1 Ki=435 nM). Enables LC-QTOF spectral libraries (NIST match >95%), microgram XRD characterization, and entourage effect modeling.

Targets EMA botanical reference programs, academic endocannabinoid consortia, and CRO bioequivalence studies. Encapsulated format excels in pharmacokinetic cross-over designs requiring blinding. Demonstrates stereoselective synthesis via CBS reduction safely.

Extends to wastewater cannabinoid epidemiology and hepatocyte uptake transporter assays.

Ordering, Availability & Fulfillment

WooCommerce platforms display graduated pricing (30-1000 count) with real-time COA batch lookup. TLS 1.3 checkout processes 99.9% PCI-DSS compliant. 24-hour fulfillment achieves 97% <48h domestic POD.

Client portals enable SDS updates, compliance certificates, and freight tracking. 99.7% OTIF supports institutional P-card cycles. Bulk institutional contracts negotiate custom fill weights.

Legal & Regulatory Disclaimer

CBD Pills 25mg CAS 13956-29-1 supplies strictly for research purposes only, not for human or veterinary use, clinical, diagnostic, or therapeutic applications. Buyers independently verify 2018 Farm Bill compliance (<0.3% Δ9-THC w/w), institutional IRB approval, and jurisdictional hemp licensing. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications. Seller disclaims liability for regulatory interpretations or non-research applications.